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echocardiographyAbstract Background: Systemic lupus erythematosus is an autoimmune disease associated with
reduced number and impaired function of endothelial progenitor cells (EPCs) responsible for
vascular regeneration.
Aim of the work: to assess left ventricular (LV) function of SLE patients using relatively new
speckle tracking echocardiography (STE) and examine the relation of any detected abnormalities
with peripheral circulating EPC level.
Patients and methods: Fifty SLE patients and 25 healthy controls were subjected to quantiﬁca-
tion of peripheral circulating Cluster of differentiation133+/vascular endothelial growth factor
receptor2+(CD133+/VEGFR2+) and CD34+/VEGFR2+ EPCs, transthoracic echocardiography
(TTE), tissue Doppler imaging (TDI) and STE.
Results: Patients showed a signiﬁcantly lower CD133+/VEGFR2+ EPCs (p= 0.009) and
CD34+/VEGFR2+ EPC counts (p= 0.0001) compared to controls. TTE/TDI revealed a signiﬁ-
cantly lower LV ejection fraction (EF) (p= 0.007), higher LV end systolic dimensions
(p= 0.02), myocardial performance index (MPI) (p= 0.0001) and mitral ﬂow E/lateral annulus
E0 ratio (p= 0.002) in patients compared to controls. STE showed a signiﬁcantly lower global
longitudinal strain (GLS) (p< 0.001), global circumferential strain (GCS) (p< 0.001) and global
S34 S.W.G. Bakhoum et al.strain rate during isovolumic relaxation period (GSRivr) (p= 0.01) in patients compared to con-
trols. By multiple logistic regression analysis, the independent variables affecting GCS and
GSRivr were the prednisolone dose and the LVEF respectively. (95% CI = 0.46 to 0.03;
p= 0.03 and 95% CI = 0.001–0.01; p= 0.021; respectively). There was no signiﬁcant correlation
of the GLS, GCS or GSRivr with the EPCs.
Conclusion: STE detected subclinical systolic and diastolic abnormalities of LV function in SLE
patients. These abnormalities of LV function did not show however any relation with the signiﬁ-
cantly lower EPC count detected in patients.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
associated with markedly increased atherosclerotic cardiovas-
cular risk [1]. Young women with lupus are over 50 times more
likely to have a myocardial infarction compared to a
population-based sample of women of similar age [2].
Endothelial dysfunction was found to signiﬁcantly contribute
to this accelerated atherosclerotic process, independently of
other classic risk factors of coronary artery disease (CAD) in
SLE patients [3].
Anti-endothelial cell antibodies have been detected in
autoimmune diseases and were found to induce endothelial cell
(EC) apoptosis [4,5]. Endothelial progenitor cells (EPCs) rep-
resent a heterogeneous group of cells released from the bone
marrow into the circulation and are thought to contribute to
vascular homeostasis and endothelial repair [6,7]. A study by
Ebner et al. [8], demonstrated that circulating mature EPCs
(CD34+/VEGFR2+) in the peripheral blood of SLE patients
are reduced in number, together with increased apoptosis,
impaired differentiation and a reduced migratory capacity.
The diminished number and the altered functionality of these
mature EPCs reduce the ability to repair vascular damage.
The number of EPCs was also found to be reduced, in heart
failure (HF) irrespective of its etiology [9]. Several abnormali-
ties of left ventricular (LV) systolic and diastolic function and
increased LV mass have been described in SLE patients
[10–12]. Whether the inherent endothelial dysfunction and
the abnormalities of EPC mobilization in SLE contribute to
this LV dysfunction is uncertain.
Speckle tracking echocardiography (STE) is a relatively
new technique that provides accurate quantitative evaluation
of regional and global LV function independent of the insona-
tion angle and cardiac translational movements [13]. The
objective of this study was to detect subclinical LV dysfunction
in SLE patients without clinically evident cardiovascular (CV)
disease using STE and correlate possible LV function abnor-
malities to circulating EPC count.2. Patients and methods
In this prospective cross sectional study, a total of 50 SLE
patients out of 75 patients screened for the inclusion and exclu-
sion criteria were recruited from the outpatient clinic or the
inpatient section of the Internal Medicine and Rheumatology
and Rehabilitation Departments of Kasr Al-Ainy Cairo
University Hospitals. They were enrolled in the study betweenJuly and September 2013. Inclusion criteria were patients
between 20 and 65 years of age with a diagnosis of SLE who
fulﬁlled at least 4 of the updated revised criteria of the
American College of Rheumatology for SLE diagnosis [14].
Exclusion criteria were patients with hypertension deﬁned as
a systolic blood pressure (BP)P 140 mmHg or diastolic
BPP90 mmHg or on antihypertensive medication, diabetes
mellitus deﬁned as a fasting blood glucose P126 mg/dl or 2-
h post-load glucose P200 mg/dl [15], history of smoking, or
signiﬁcant valvular heart disease. Twenty-ﬁve healthy age
and gender matched subjects served as controls. The research
protocol was approved by the ethics committee of Cairo
University Hospital. The study was conducted in accordance
with the Declaration of Helsinki. Written, informed consent
was obtained from each patient.
The disease activity was assessed using the SLE disease
activity index (SLEDAI) scoring system [16]. Information con-
cerning disease duration and medications used was recorded.
A blood sample was collected from all patients and controls
for EPC count estimation in addition to routine laboratory
workup including complete blood count, high sensitivity C-
reactive protein (HsCRP) estimated by ELISA, erythrocyte
sedimentation rate (ESR), renal function tests, total choles-
terol and triglyceride levels, fasting blood glucose, anti-
nuclear antibodies (ANA), and anti-double stranded deoxyri-
bonucleic acid antibodies (Anti ds-DNA).2.1. EPC identiﬁcation and counting by ﬂow cytometry (FC)
analysis
Phycoerythrin (PE)-labeled monoclonal anti-CD34 & anti-
CD133 (Cat. No. 130-081-002; Miltenyi Biotec, Germany),
ﬂuorescein-labeled monoclonal anti-VEGFR2/KDR (Cat.
No. FAB357F; R&D/UK) were used for the characterization
of circulating EPCs. Isotype and ﬂuorochrome-matched con-
trol antibodies (Abs) (Mouse IgG1-FITC and IgG1-PE) were
used for setting ﬂuorescence markers around negative popula-
tion and detecting non-antigen speciﬁc antibody binding.
EDTA venous blood collected from patients and controls
and kept at room temperature was analyzed within 24 h of
venipuncture. For red blood cell lysis, peripheral blood sam-
ples were diluted in 15 ml bicarbonate-buffered ammonium
chloride solution for 15 min at room temperature. The cells
were centrifuged and re-suspended in 2 ml FC staining buffer
(Cat. No. FC001; R&D/UK). The number of cells was
adjusted to 1 · 106 cells/ml. The cells were then prepared into
three test tubes, containing 100 ll of cell suspension each,
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speciﬁc binding) and 10 ll 7-AAD (to exclude dead cells from
FC analysis). The ﬁrst tube contained as well VEGFR2-
Fluorescein and CD133/1-PE monoclonal Abs; the second
tube contained as well VEGFR2-Fluorescein and CD34-PE
monoclonal Abs while the third tube contained as well 10 ll
of the matched isotypic control. Positive staining was deﬁned
as being greater than non-speciﬁc background staining. All
samples were measured in duplicate. The lymphocyte fraction
was identiﬁed on a forward/side scatter, and a minimum of
1 · 105 lymphocytes were counted. Cells positive for
VEGFR2/CD133 were characterized as early EPCs, whereas
cells positive for VEGFR2/CD34 within the lymphocyte frac-
tion were characterized as mature EPCs. Results were
expressed as the number of EPCs per 1 · 106 lymphocytes.
3. Echocardiography
3.1. Transthoracic echocardiography (TTE) and tissue Doppler
imaging (TDI)
TTE and TDI were performed to all patients and controls
using a commercially available echocardiography machine
(ESAOTE MY LAB 60) equipped with broadband
S1-5 MHz transducer in the Cardiology Department of Kasr
Al-Ainy Cairo University Hospitals. After a 10-min rest, sub-
jects were examined in the left lateral decubitus position to
obtain adequate images in different standard views. Left atrial,
aortic diastolic, LV end-diastolic dimensions (LVEDD), and
LV end-systolic dimensions (LVESD) were measured using
M-mode echocardiography. Left ventricular ejection fraction
(LVEF) was obtained by the biplane Simpson’s method.
Trans-mitral pulsed wave Doppler velocities were recorded
from the apical four-chamber (4-CH) view.
Early (E) and late (A) wave peak velocities, E/A ratio, E
deceleration time (E-DT) were measured. By placing the
Doppler sample volume midway between the mitral inﬂow
and aortic outﬂow tract, trans-mitral and trans-aortic
Doppler ﬂows were recorded simultaneously. The ejection
time (ET), isovolumic contraction time (ICT) and isovolumic
relaxation time (IVRT) were measured and myocardial
performance index (MPI) was calculated as the ratio:
IVRT + IVCT/ET. The myocardial systolic (S), early diastolic
(E0), and late diastolic (A0) peak velocities were obtained at the
lateral and septal corners of the mitral annulus in the
4-chamber (4-CH) view by pulsed wave tissue Doppler keeping
the angle between the beam and the wall motion direction
<15. The E/lateral annulus E0 (E/E0) ratio was subsequently
calculated. All the above measures were recorded as the aver-
age of three consecutive cycles.
3.2. Speckle tracking echocardiography (STE)
Myocardial deformation measurements were obtained using
STE. The analysis was performed on grayscale images of
the LV obtained in the apical 4-CH, 2-chamber (2-CH)
and short-axis mid-ventricular views. Three consecutive
end-expiratory cardiac cycles using high frame rate >80 s1
harmonic imaging in each echocardiographic view were
acquired. Data were analyzed off-line using dedicated software
(ESAOTE MY LAB 60) on one cardiac cycle. The analysis isinitiated by deﬁning manually in the apical views three endo-
cardial landmarks at the lateral and medial corners of the
mitral annulus and the LV cardiac apex and in the mid ventric-
ular short axis views two landmarks at the inferior septum and
the lateral wall. Manual adjustment of the segments of interest
was performed when necessary. Thereafter, the software auto-
matically analyzed different segments of interest. From the
apical 4-CH view, longitudinal strain was assessed through
basal, mid apical septal, basal, mid and apical lateral wall seg-
ments. From the apical 2-CH view, longitudinal strain was
assessed through basal, mid, apical inferior, basal, mid, and
apical anterior wall segments. The global longitudinal strain
(GLS) was calculated as the average of the LS of the 12
myocardial segments of the 4-CH and 2-CH views. From the
short axis view at the level of the papillary muscles, the circum-
ferential strain was assessed through the mid-segments of the
anteroseptal, anterior, anterolateral, inferolateral, inferior,
and inferoseptal walls. The global circumferential strain
(GCS) was calculated as the average of the CS of the 6 mid
myocardial segments of the ventricular short axis view. The
global longitudinal systolic strain rate (GSSR), global diastolic
strain rate during the IVR period (GSRivr), early diastole
(GSRe) and late diastole (GSRa) were calculated as the average
of the SR of the 12 myocardial segments of the 4-CH and the
2-CH views.
Statistical analysis: Normally distributed continuous
variables were expressed as mean ± SD while continuous
variables with non-normal distribution were presented as med-
ian values and interquartile range (IQR). Categorical data
were expressed as percentages. Differences between groups
were assessed by unpaired 2-tailed t test and the Mann–
Whitney U test for continuous variables, according to whether
they were normally distributed or not. Categorical data and
proportions were analyzed by the use of chi-square or
Fisher’s exact test when required. Pearson and Spearman’s
correlation were used to assess the correlation between differ-
ent variables. Univariate and multivariate linear regression
analyses were used to investigate possible associations between
STE LV deformation abnormalities and other studied vari-
ables. A signiﬁcance level of p < 0.05 was used in all tests.
All statistical procedures were carried out using SPSS version
15 for Windows (SPSS Inc., Chicago, IL, USA).4. Results
A total of 50 SLE patients were included in the study; 47
females and 3 males. The median disease duration was
4.5 years with an IQR of 2–7.25 years. The mean SLEDAI
score was 5.9 ± 5.75 (range: 0–20). All patients were receiving
prednisolone with a median duration of 54 months (IQR: 24–
96 months). The median prednisolone dose was 7.5 mg (IQR:
5–15 mg). Twenty-ﬁve subjects with comparable age and gen-
der were included. Patients had a signiﬁcantly higher ESR
(p< 0.001), HsCRP (p= 0.005), total serum cholesterol
(p= 0.001), serum triglycerides (p= 0.001) and alanine
transaminase (p= 0.01) compared to the control. The com-
parison of the demographic and laboratory data between the
patients and controls is shown in Table 1.
The CD133+/VEGFR2+ and CD34+/VEGFR2+ EPC
counts were signiﬁcantly lower in patients compared to controls
(p= 0.009 and p= 0.0001, respectively). No signiﬁcant
Table 1 Demographic and laboratory data of systemic lupus







Age (years) 28.5 ± 8.5 30.2 ± 10.2 0.45
Female/male 47/3 23/2 1
BMI 26.5 ± 2.3 24.7 ± 1.9 0.001
Laboratory
ESR (mm/h) 72.5 (35–110) 16 (11–24) <0.001
Hs CRP (mg/dl) 0.7 (0.31–1.52) 0.35 (0.23–0.79) 0.005
Hb (gm/dl) 10.3 ± 1.3 13.2 ± 1.5 0.001
WBCs (·103/mm3) 7 ± 3.8 7 ± 2.4 0.9
Platelets (·103/mm3) 234.7 ± 118.3 244.5 ± 105.9 0.7
Creatinine (mg/dl) 1 ± 0.4 0.9 ± 0.3 0.1
Albumin (g/dl) 3.7 ± 0.5 3.9 ± 0.9 0.09
Cholesterol (mg/dl) 210.1 ± 74.5 169.6 ± 26.7 0.001
Triglycerides (mg/dl) 163.2 ± 67.6 93.2 ± 21.6 0.001
AST (IU/l) 21.5 ± 7 19.2 ± 5.8 0.1




5 (3–12) 109 (3–429) 0.009
CD34+/VEGFR2+ 3.5 (2–9) 63 (5–104) 0.0001
BMI: body mass index; ESR: erythrocyte sedimentation rate; Hs
CRP: high sensitivity C-reactive protein; Hb: hemoglobin; WBC:
white blood cells; AST: aspartate transaminase; ALT: alanine
transaminase; VEGFR: vascular endothelial growth factor recep-
tor; EPCs: endothelial progenitor cells. Ly: lymphocytes. Results
are presented as mean ± SD or as median (Interquartile range).
Bold ﬁgures mean signiﬁcant p value.
Table 2 Transthoracic Echocardiography (TTE) and tissue
Doppler imaging (TDI) data for the systemic lupus erythe-









LVSWT (mm) 8.1 ± 1.8 7.9 ± 1.6 0.6
LVEDD (mm) 49.6 ± 6.4 47.3 ± 5.4 0.1
LVPWT (mm) 7.8 ± 1.5 7.7 ± 1.3 0.8
LVESD (mm) 33.0 ± 6.1 29.6 ± 5.6 0.02
EF (%) 64.0 ± 6.7 68.8 ± 7.7 0.007
Ao (mm) 25.2 ± 2.9 24.6 ± 2.9 0.4
LA (mm) 33.6 ± 5.5 31.3 ± 4.3 0.08
Transmitral velocity
E wave (cm/s) 90 ± 20 80 ± 20 0.1
A wave (cm/s) 80 ± 20 60 ± 10 0.002
E/A ratio 1.3 ± 0.4 1.4 ± 0.4 0.2
E-DT (ms) 179.3 ± 37.8 170.4 ± 41.3 0.4
IVRT (ms) 75.7 ± 13.4 58.6 ± 6.1 0.01
MPI 0.62 ± 0.12 0.49 ± 0.05 0.0001
Tissue Doppler imaging
Med E0 (cm/s) 8.7 ± 2.9 11.4 ± 4 0.002
Med A0 (cm/s) 6.2 ± 2.5 5.3 ± 1.7 0.07
Med S0 (cm/s) 7.5 ± 1.6 7.5 ± 2.1 0.9
Lat E0 (cm/s) 9.0 ± 4.0 11.7 ± 3.4 0.01
Lat A0 (cm/s) 7.0 ± 3.8 6.4 ± 1.8 0.3
Lat S0 (cm/s) 8.3 ± 1.6 8.8 ± 2.2 0.4
Lat E/E0 11.1 ± 5 7.6 ± 2.2 0.002
TEE: Transthoracic Echocardiography; LVSWT: left ventricular
septal wall thickness; LVEDD: left ventricular end diastolic
dimension; LV PWT: left ventricular posterior wall thickness;
LVESD: left ventricular end systolic dimension; EF: ejection frac-
tion; Ao: aorta; LA: left atrium; MPI: myocardial performance
index; E-DT: E wave deceleration time; Lat: lateral; Med: medial;
IVRT: isovolumic relaxation time. Bold values mean signiﬁcant p
value.
S36 S.W.G. Bakhoum et al.correlation was detected between CD133+/VEGFR2+ or
CD34+/VEGFR2+ EPC count and age of patients (r= 0.21,
p= 0.2 and r= 0.13; p= 0.4 respectively), disease duration
(r= 0.08, p= 0.6 and r= 0.01; p= 1 respectively), pred-
nisolone dose (r= 0.02, p= 0.9 and r= 0.04; p= 0.8 respec-
tively), prednisolone duration (r= 0.05, p= 0.7 and
r= 0.03; p= 0.9 respectively), SLEDAI score (r= 0.19,
p= 0.2 and r= 0.23; p= 0.1 respectively), BMI (r= 0.03,
p= 0.8 and r= 0.001; p= 1 respectively), Hs CRP
(r= 0.26, p= 0.06 and r= 0.27; p= 0.06 respectively) or
ESR (r= 0.17, p= 0.3 and r= 0.26; p= 0.07 respectively).
4.1. Echocardiographic data
4.1.1. M-mode, two-dimensional Doppler measurements
The LVESD was signiﬁcantly greater (p= 0.02) while the
LVEF was signiﬁcantly lower in patients (p= 0.007) com-
pared to controls. Trans-mitral ﬂow A wave velocity was sig-
niﬁcantly higher (p= 0.002) and the IVRT signiﬁcantly
prolonged (p= 0.01) in patients compared to controls. The
MPI was also signiﬁcantly higher in patients (p= 0.0001).
4.1.2. Tissue Doppler imaging (TDI) measurements
The medial and lateral mitral annulus E0 wave velocities were
signiﬁcantly lower in patients compared to controls (p= 0.002
and p= 0.01, respectively). The lateral E/lateral E0 ratio was
signiﬁcantly higher in patients compared to controls(p= 0.002). The detailed TTE and TDI measurements of the
patients and controls are shown in Table 2.
4.1.3. Speckle tracking echocardiography (STE) measurements
The GLS and GCS were signiﬁcantly lower in patients com-
pared to controls (p< 0.001 in both) (Fig. 1). The GSRivr
was signiﬁcantly lower in patients compared to controls
(p= 0.01). The detailed STE measurements of patients and
controls are listed in Table 3. Univariate logistic regression
was used to investigate possible associations between the
GLS, GCS, GSRivr and the following variables: age of
patients, duration of disease, prednisolone dose, prednisolone
intake duration, use of azathioprine vs. cyclophosphamide,
SLEDAI score, MPI, LVEF, CD133+/VEGFR2+ EPC count
and CD34+/VEGFR2+ EPC count. There was no signiﬁcant
correlation between any of the studied variables and GLS
either by univariate or multivariate analysis. Using univariate
analysis, there was no signiﬁcant correlation between studied
variables and GCS except for prednisolone dose. After adjust-
ment for all variables using multiple logistic regression model,
prednisolone dose remained the only independent variable
affecting GCS (adjusted regression coefﬁcient = 0.24, 95%
CI = 0.46 to 0.03; p= 0.03). As regards GSRivr, LVEF
was the only variable affecting it by both univariate and
multivariate logistic regression analyses (adjusted regression
Figure 1 Automatically generated left ventricular (LV) deformation curves by the software (my lab60). (A) LV circumferential strain in
the short axis view at the level of papillary muscles. (B) LV longitudinal strain in the four–chamber view. (C) LV longitudinal strain in the
two–chamber view. (D) LV strain rate in the two–chamber view. The curves in white represent the average (global) strain or strain rates of
different studied LV segments.
Left ventricular function in systemic lupus erythematosus patients S37coefﬁcient = 2.4, 95% CI = 0.001–0.01; p= 0.021). The
detailed multivariate linear regression analysis of the different
factors affecting GLS, GCS and GSRivr is shown in Table 4.
5. Discussion
The current study demonstrated signiﬁcantly reduced
CD133+/VEGFR2+and CD34+/VEGFR2+ EPC count in
SLE patients compared to controls. Experimental and clinical
studies have demonstrated the important role of EPCs in tissue
regeneration including neoangiogenesis, reendothelialization,
repair of injured arteries and improvement of LV function fol-
lowing myocardial infarction [6,17–21]. The current study ﬁnd-
ing of low EPCs in SLE patients is in agreement with the
results of several other studies. Denny et al. [22] reported a sig-
niﬁcant decrease of CD34+/CD133+ EPCs and myelomono-
cytic circulating angiogenic cells (CACs) and a signiﬁcant
correlation of EPC count with SLEDAI score but not with
the use of speciﬁc medications or daily corticosteroid doses.
However, even those individuals with no clinical or serologic
disease activity (SLEDAI = 0) had pronounced EPC decrease
compared with controls. Lee et al. [23] demonstrated a mark-
edly reduced level of EPC colony-forming units and the deple-
tion of EPCs was more dramatic in SLE patients with elevated
levels of IFN-I. The reduced EPC levels were not explained by
use of common medications including steroids, anti-malarials,
cytotoxic agents, or statins.
In our study, we could not ﬁnd any signiﬁcant correlation
between EPC count and disease duration, SLEDAI score, pred-
nisolone dose or duration of intake, HsCRP or ESR. The
reduction of EPCs was even reported in SLE patients in aninactive stage of disease, or in prolonged clinical remission
[24,25]. Ebner et al. [8] reported an enhanced
VEGFR2+/CD133+ EPC number whereas the number of
VEGFR2+/CD34+ cells and the proliferation rate were signif-
icantly decreased. In the current study, the levels of immature
VEGFR2+/CD133+ and mature VEGFR2+/CD34+ cells
were reduced. The decrease in the number of circulating
EPCs was also described in other diseases with vascular inﬂam-
matory components, for example, rheumatoid arthritis and
chronic renal failure [26,27]. The low levels of circulating
EPCs in our study could be attributed to increased oxidative
stress related to the inﬂammatory process associated with
SLE and which was shown to inhibit EPC differentiation,
survival, and function [28]. An alternative explanation is that
continuous endothelial damage or dysfunction leads to an even-
tual depletion or exhaustion of a presumed ﬁnite supply of EPCs
involved in vascular homeostasis and endothelial repair. SLE
has been shown to be an independent risk factor for endothelial
dysfunction [3]. In a recent study of 38 lupus women without
detectable myocardial ischemia on myocardial perfusion imag-
ing, brachial artery ﬂow mediated vasodilatation as a marker
of endothelial function correlated strongly with E/E0 as a marker
of LV diastolic function independent of systolic blood pressure,
age, or lupus clinical damage index [29].
The second important ﬁnding of the current study is the
echocardiographic abnormalities of both systolic and diastolic
function in SLE patients with no clinically apparent CV dis-
ease. Echocardiographic cardiac abnormalities were described
more than 3 decades ago in SLE [30–32]. To the best of our
knowledge, this the ﬁrst study to investigate the correlation
between LV deformation abnormalities as detected by STE
Table 3 Speckle tracking echocardiography (STE) data for the systemic lupus erythematosus patients and controls.
STE data Patients (n= 50) Control (n= 25) p value
4-Chamber view longitudinal strain (%)
Basal septal 14.3 ± 5.5 16.6 ± 2.6 0.01
Mid septal 16.2 ± 4.3 18.7 ± 2.3 0.002
Apical septal 18.3 ± 6.3 20.3 ± 3.7 0.2
Basal lateral 14.9 ± 3.7 19.8 ± 4.8 <0.001
Mid lateral 14.8 ± 3.8 19.1 ± 3.8 <0.001
Apical lateral 19.9 ± 26.7 18.2 ± 2.8 0.8
2-Chamber view longitudinal strain (%)
Basal inferior 11.1 ± 5.8 19.6 ± 4.3 <0.001
Mid inferior 13.5 ± 4.2 18.6 ± 2.9 <0.001
Apical inferior 14.9 ± 5.4 19.7 ± 4.1 <0.001
Basal anterior 13.2 ± 5.9 21.0 ± 5.2 <0.001
Mid anterior 13.1 ± 4.9 19.2 ± 5.0 <0.001
Apical anterior 12.7 ± 5.2 17.1 ± 4.1 <0.001
GLS (%) 14.5 ± 2.8 19.0 ± 1.3 <0.001
SAX view circumferential strain (%)
Mid anteroseptal 23.6 ± 11.0 30.3 ± 11.7 0.02
Mid anterior 20.5 ± 11.5 29.6 ± 11.5 0.002
Mid anterolateral 16.5 ± 7.4 24.6 ± 9.2 <0.001
Mid inferolateral 16.2 ± 6.0 22.7 ± 6.9 <0.001
Mid inferior 17.8 ± 6.5 24.3 ± 8.1 <0.001
Mid inferoseptal 21.0 ± 7.7 25.6 ± 9.1 0.04
GCS (%) 19.3 ± 6.8 26.2 ± 6.9 <0.001
GSR longitudinal systolic (1/s) 1.0 ± 0.2 1.1 ± 0.2 0.2
GSR longitudinal diastolic (1/s)
GSRivr 0.14 ± 0.09 0.2 ± 0.1 0.01
GSRe 1.2 ± 0.3 1.3 ± 0.2 0.1
GSRa 0.8 ± 0.3 0.7 ± 0.2 0.2
STE: speckle tracking echocardiography; SAX: GLS: global longitudinal strain; GCS: global circumferential strain; GSR: global strain rate; ivr:
isovolumic relaxation period; GSRe: global strain rate during early diastole; GSRa: global strain rate during atrial contraction; SAX: short axis.
Bold values mean signiﬁcant p value.
Table 4 Factors affecting global longitudinal strain (GLS), global circumferential strain (GCS) and global strain rate (GSR) during
isovolumic relaxation period.
Variables GLS GCS GSRivr
ARC (95% CI) p ARC (95% CI) p ARC (95% CI) p
Age 0.07 (0.06 to 0.19) 0.3 0.09 (0.2 to 0.4) 0.5 1.1 (0.002 to 0.01) 0.3
Disease duration 0.3 (1.18 to 0.19) 0.7 0.68 (2.6 to 4) 0.7 0.1 (0.05 to 0.05) 0.9
Steroid dose 0.007 (0.10 to 0.09) 0.9 0.24 (0.5 to 0.03) 0.03 0.1 (0.003 to 0.003) 0.9
Steroid duration 0.09 (1.52 to 1.34) 0.9 1.01 (4.4 to 2.2) 0.5 0.5 (0.04 to 0.06) 0.6
AZA/CYC 2.5 (0.49 to 5.48) 0.1 1.63 (5.2 to 8.4) 0.6 1.7 (0.02 to 0.19) 0.09
SLEDAI score 0.04 (0.2 to 0.12) 0.7 0.03 (0.3 to 0.4) 0.9 0.6 (0.01 to 0.004) 0.6
MPI 1.4 (5.64 to 7.51) 0.7 13.6 (2.5 to 29.7) 0.1 1.3 (0.001 to 0.01) 0.2
LVEF 0.08 (0.22 to 0.05) 0.2 0.08 (0.2 to 0.4) 0.6 2.4 (0.001 to 0.01) 0.02
EPCs
VEGFR2+/CD133+ 0.002 (0.01 to 0.02) 0.8 0.01 (0.04 to 0.02) 0.5 0.7 (0.00001 to 0.001) 0.5
VEGFR2+/CD34+ 0.006 (0.06 to 0.05) 0.82 0.01 (0.12 to 0.14) 0.9 1.01 (0.003 to 0.001) 0.3
GLS: global longitudinal strain; GCS: global circumferential strain; GSRivr: global strain rate during isovolumic relaxation period; ARC:
adjusted regression coefﬁcient; CI: conﬁdence interval; AZA/CYC: azathioprine/cyclophosphamide; SLEDAI: systemic lupus erythematosus
disease activity index; MPI: myocardial performance index; LVEF: left ventricular ejection fraction; EPCs: endothelial progenitor cells. Bold
values mean signiﬁcant p value.
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As regards conventional TTE and TDI ﬁndings, SLE patients
in the present study had a signiﬁcantly higher LVESD com-
pared to controls (p= 0.02). Although the LVEF of thepatients was in the normal range, it was signiﬁcantly lower
compared to controls (p= 0.007) suggesting subclinical sys-
tolic dysfunction. The IVRT was signiﬁcantly prolonged and
the MPI was signiﬁcantly higher in patients compared to
Left ventricular function in systemic lupus erythematosus patients S39controls denoting diastolic dysfunction as well. In agreement
with our results, a signiﬁcantly lower LVEF was reported in
SLE patients compared to controls (p< 0.001) in a study of
50 SLE patients. A signiﬁcantly higher interventricular septum
(IVS) and posterior wall (PW) dimensions, and Doppler mitral
A/E ratio in patients compared to controls have been demon-
strated [33]. In our study, there was no statistically signiﬁcant
difference in IVS, PW dimensions or trans-mitral ﬂow Doppler
E/A ratio between the patients and controls. A study compar-
ing patients with SLE to those with antiphospholipid
syndrome (APS), lupus patients had higher LVEDD and
LVESD (p= 0.022 and 0.022, respectively), with a trend
toward a lower fractional shortening (p= 0.07) compared to
primary APS [10]. Cacciapuoti et al. [34] used TDI to calculate
IVRT and MPI in 44 SLE patients without clinical signs of
heart disease, and found as well signiﬁcantly higher IVRT
and MPI in patients compared to controls. The current study
also demonstrated a signiﬁcantly higher E/lateral E0 ratio in
patients compared to controls (p= 0.002) pointing again to
diastolic dysfunction. Similarly, Lee et al. [35] reported a
higher E/E0 in SLE patients compared to controls despite a
normal Doppler ﬂow E/A ratio (p< 0.01) This study also
described a lower E/E0 ratio and higher LVEF in SLE patients
receiving angiotensin converting enzyme inhibitors (ACE-Is)
or angiotensin receptor blockers (ARBs) compared to those
not receiving these medications indicating their role in preserv-
ing LV diastolic and systolic functions. None of our patients
were receiving ACE-Is or ARBs because we excluded SLE
hypertensive patients and the patients included were free of
clinically manifest CV disease.
As regards STE ﬁndings, the current study revealed a signif-
icantly lower LV GLS (p< 0.001), LV GCS (p< 0.001) and
GSRivr (p= 0.01) in patients compared to controls. There
was no signiﬁcant correlation between any of the studied vari-
ables and GLS. By multiple logistic regression analysis, the
independent variables affecting GCS and GSRivr were the
prednisolone dose and the LVEF respectively. (p= 0.028
and p= 0.021; respectively). These ﬁndings were in agreement
with some aspects of the study by Buss et al. [36] who used
TDI to calculate LV strain and strain rates in 67 young SLE
patients. This study not only demonstrated signiﬁcantly
reduced GLS; a ﬁnding similar to our study but also detected
signiﬁcantly reduced GSSR, GSRe, GSRa in patients com-
pared to controls. Further, elevated SLEDAI score, resulted
in signiﬁcantly lower values for LV longitudinal function strain
and strain rate. In the current study, we could not ﬁnd any sta-
tistically signiﬁcant difference in GSSR, GSRe, GSRa between
patients and controls. In a recent study using three-
dimensional (3D) STE, although no difference in LV global
systolic function was noted by standard echocardiography
between patients and controls, 3D LVEF, LV GLS, LVGCS,
LV global area stain (GAS) and global radial strain (GRS)
were largely impaired in patients [37]. This study demonstrated
also that GLS, GAS, GRS but not GCS were signiﬁcantly
decreased in those with severe disease activity than among
those with no or mild activity (all p< 0.05). GLS was also
independently correlated with SLEDAI score (p= 0.001).
Yip et al. [12] showed that SLEDAI P1 was an independent
predictor of LV longitudinal systolic dysfunction in SLE
patients using TDI. In the present study, no correlation was
detected between SLEDAI score and the different myocardial
deformation parameters. The lack of a signiﬁcant correlationbetween SLEDAI score and evident LV diastolic dysfunction
in SLE patients has been described before in previous studies
[38,39]. In the present study, these LV subclinical abnormali-
ties cannot be explained by increased prevalence of traditional
CV risk factors such as smoking, HTN or DM because
patients having them were excluded. The patients had however
signiﬁcantly higher cholesterol and triglyceride levels com-
pared to controls. This may be the result of prednisolone
which was prescribed to all patients. It is generally perceived
that glucocorticoids have adverse effect on the lipid proﬁle
causing increase in both total cholesterol and triglycerides
[40,41]. This high level of cholesterol and triglycerides may
have induced subclinical coronary atherosclerosis in our
patients. A high prevalence of myocardial perfusion abnormal-
ities were detected in asymptomatic SLE patients without overt
CV disease using single photon emission computed tomogra-
phy [42,43]. In a study by Doria et al. [44], subclinical
atherosclerosis has been shown to be more prevalent in SLE
patients. Patients with carotid abnormalities were signiﬁcantly
older, had higher blood pressure and total serum cholesterol
levels, and had taken a higher prednisone cumulative dosage
than those without any lesions. By multivariate analysis, the
cumulative prednisone dose remained associated with plaque
formation after adjusting it for the classical Framingham
atherosclerosis risk predictors. A signiﬁcant association
between carotid plaque formation in SLE patients and cumu-
lative corticosteroid dosage as well as duration of treatment
has been also reported by Manzi et al. [45]. In another study
on Egyptian SLE patients, an increased prevalence of subclin-
ical LV dysfunction was reported. SLE patients with positive
tissue Doppler ﬁndings were of old age, had long disease dura-
tion, high disease activity and nephritis [46]. In the current
study, the prednisolone dose was the only independent variable
adversely affecting LV GCS (p= 0.028). In a study of diabetic
patients, those with coronary atherosclerosis as evidenced by
increased calcium score in multi-slice computerized tomogra-
phy scanner showed an impaired LV GLS, even though the
LVEF was still preserved compared to those with no evidence
of coronary atherosclerosis [47]. Hence, premature subclinical
atherosclerosis may be the underlying cause of these subtle
changes in LV function.
When we designed the current study, we hypothesized that
EPCs might have a relation to any possible detected systolic or
diastolic LV function abnormalities in SLE patients. These
speculations were based on the ﬁndings of previous studies
correlating EPC count to LV remodeling and function
[9,21,48,49]. Peripheral blood CD34+ cells and EPC mobiliza-
tion occurs in heart failure (HF) and shows a biphasic
response, with elevation and depression in the early and
advanced phases, respectively [48]. In a study by Kissel et al.
[9], the number of EPCs was found to be reduced, irrespective
of the etiology of HF, whether ischemic or dilated cardiomy-
opathy. On the other hand, in a study by Leone et al. [49],
the concentration of CD34+ bone marrow derived stem cells
was not only higher in acute myocardial infarction (AMI)
patients compared to patients with stable CAD but was also
an independent predictor of global and regional improvement
of LV function at the end of 1 year follow-up. In the
TOPCARE-AMI trial, intracoronary infusion of circulating
EPCs in patients with AMI resulted in an increased EF,
reduced infarct size, and absence of reactive hypertrophy, sug-
gesting functional regeneration of the infarcted ventricles at
S40 S.W.G. Bakhoum et al.the end of 1 year follow-up. In the current study, the inability
to detect a statistically signiﬁcant correlation between the EPC
count and LV deformation abnormalities could be attributed
to their detection in a quite early stage using STE or because
of the small number of patients studied.
The ﬁrst limitation is the cross sectional design of the study.
The patients were not followed up to be able to examine the
progression of LV systolic and diastolic abnormalities detected
by STE or the effect of the low circulating EPCs on these
abnormalities over time. The second limitation is the relatively
small number of patients. This can be explained by the rigor-
ous exclusion criteria. We actually excluded patients with clas-
sical risk factors such as smoking, HTN or DM which were
quite prevalent in lupus patients to avoid the impact of these
factors on LV function.
In conclusion the relatively new STE can be used to diag-
nose subtle abnormalities in LV function in SLE patients
which could not be detected by conventional TTE or TDI.
The low count of circulating EPCs detected in these patients
was probably the result of the inﬂammatory process associated
with SLE rather than early LV dysfunction which could only
be detected by STE.Conﬂict of interest
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